Understanding How Lupus and Cancer Interact
Global Gastric Cancer Diagnostics Market Is Expected To Expand At A CAGR Of ~7% By 2030DelveInsight
The increasing global incidence of gastric cancer is a major factor driving the demand for gastric cancer diagnostics. The market is also being fueled by the rising prevalence of GERD and other stomach-related conditions, along with the growing number of stomach infections such as H. Pylori and gastroenteritis. Additionally, the surge in obesity and smoking, which are linked to the development of stomach cancer, are significant contributors to the market's growth during the forecast period from 2024 to 2030.
LAS VEGAS, Sept. 3, 2024 /PRNewswire/ -- DelveInsight's Gastric Cancer Diagnostics Market Insights report provides the current and forecast market analysis, individual leading gastric cancer diagnostics companies' market shares, challenges, gastric cancer diagnostics market drivers, barriers, trends, and key market gastric cancer diagnostics companies in the market.
DelveInsight Business Research Logo
Key Takeaways from the Gastric Cancer Diagnostics Market Report
As per DelveInsight estimates, North America is anticipated to dominate the global gastric cancer diagnostics market during the forecast period.
In the product type segment of the gastric cancer diagnostics market, the reagents & kits category generated a significant revenue share in the gastric cancer diagnostics market in 2023.
Notable gastric cancer diagnostics companies such as Abbott, BD, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, Siemens Healthineers AG, Thermo Fisher Scientific Inc., Pillar Biosciences Inc., Hologic, Inc., CD Genomics, Natera, Inc., Biodesix, Illumina, Inc., Quest Diagnostics, Agilent Technologies, Inc., FUJIFILM Holdings Corporation, NeoGenomics Laboratories, Guardant Health, Myriad Genetics, Inc., Invitae Corporation, Danaher, and several others, are currently operating in the gastric cancer diagnostics market.
In March 2024, AI Medical Service Inc. Announced that it had launched gastroAI-model G, an AI-based endoscopic diagnostic support device that operates within the stomach. The diagnostic device operates by scanning for potential lesions, utilizing images derived from the video processor of the endoscopy system. Upon determining that a lesion appears suspicious for early gastric cancer and requires additional evaluation, the program notifies the physician and offers diagnostic support by presenting a highlighted area within the endoscopic display.
In November 2023, Dedalus Group in collaboration with Ibex Medical Analytics, announced the launch of a fully integrated AI-powered digital pathology solution for gastric cancer diagnosis.
In August 2023, Mirxes Pte Ltd announced that its flagship product GASTROClear, a PCR-based in vitro diagnostic test for early detection of gastric (stomach) cancer, has been granted Breakthrough Device Designation by the U.S. Food and Drug Administration (FDA). It is a molecular blood test for the early detection of gastric cancer that helps to cure cancer with affordable treatment.
To read more about the latest highlights related to the gastric cancer diagnostics market, get a snapshot of the key highlights entailed in the Global Gastric Cancer Diagnostics Market Report
Gastric Cancer Diagnostics Overview
Gastric cancer, or stomach cancer, is typically diagnosed through a combination of clinical evaluation, imaging techniques, and tissue biopsy. The diagnostic process often begins with a patient's history and physical examination, focusing on symptoms like persistent indigestion, weight loss, and abdominal pain. Imaging studies, such as upper gastrointestinal endoscopy, are crucial as they allow direct visualization of the stomach lining. During an endoscopy, a flexible tube with a camera is inserted through the mouth into the stomach, enabling doctors to identify suspicious lesions or tumors. Additional imaging techniques, such as computed tomography (CT) scans or positron emission tomography (PET) scans, may be used to determine the extent of the cancer and to detect possible metastasis to other organs.
Confirming a diagnosis of gastric cancer requires a biopsy, where tissue samples are taken during an endoscopy and examined under a microscope for cancerous cells. Histopathological analysis of the biopsy helps determine the type and grade of the cancer, which is critical for guiding treatment options. Molecular testing on the biopsy sample can also identify specific genetic mutations or protein expressions, such as HER2, which may influence targeted therapy decisions. Blood tests for tumor markers like carcinoembryonic antigen (CEA) and CA 19-9 are sometimes used to support diagnosis or monitor treatment response, although these markers are not specific to gastric cancer. Early and accurate diagnosis is essential in improving the prognosis and survival rates for patients with gastric cancer.
Gastric Cancer Diagnostics Market Insights
In 2023, North America held the largest share of the gastric cancer diagnostics market. This dominance is attributed to the increasing prevalence of gastric cancer and related stomach diseases, along with the region's growing geriatric population and advancements in early cancer detection technologies. Data from the American Cancer Society, published in January 2024, predicts approximately 26,890 new cases of stomach cancer in the United States for 2024, with 16,160 cases among men and 10,730 among women. Stomach cancer accounts for about 1.5% of all new cancer diagnoses annually in the country.
The higher incidence of gastric cancer among older adults is linked to age-related risk factors such as stomach infections and gastroesophageal reflux disease (GERD). As a result, the expanding elderly population is expected to drive the growth of the gastric cancer diagnostics market in the region.
In March 2024, Ibex Medical Analytics launched Galen, an AI-powered diagnostic platform that offers accurate cancer diagnoses, reduces manual tasks, and is used for diagnosing gastric cancer, H. Pylori, and other gastric lesions like adenoma and low-grade dysplasia. This increase in R&D activities by major players to develop advanced diagnostic solutions is expected to further boost the North American gastric cancer diagnostics market.
To know more about why North America is leading the market growth in the gastric cancer diagnostics market, get a snapshot of the Gastric Cancer Diagnostics Market Outlook
Gastric Cancer Diagnostics Market Dynamics
The gastric cancer diagnostics market is evolving rapidly, driven by technological advancements, increasing awareness, and a growing focus on early detection. Gastric cancer, which remains one of the leading causes of cancer-related mortality worldwide, particularly in Asia and Eastern Europe, has led to a pressing need for improved diagnostic methods. Traditional diagnostic techniques like endoscopy and biopsy are now being complemented and, in some cases, replaced by innovative, non-invasive technologies such as liquid biopsy, molecular diagnostics, and advanced imaging techniques. These new modalities offer the potential for earlier detection, more accurate staging, and better monitoring of disease progression, which is critical for improving patient outcomes.
A significant dynamic in the market is the integration of molecular diagnostics, including next-generation sequencing (NGS), which allows for the detection of specific genetic mutations and biomarkers associated with gastric cancer. These advancements are not only enhancing the precision of diagnosis but also paving the way for personalized medicine, where treatment can be tailored based on an individual's genetic profile. The push towards personalized medicine is further fueling the demand for diagnostic tools that can provide comprehensive genomic data, leading to an increase in partnerships between diagnostic companies and pharmaceutical firms aiming to develop targeted therapies.
Furthermore, the rise of artificial intelligence and machine learning in diagnostics is another key trend shaping the gastric cancer diagnostics market. AI and ML are being integrated into imaging and pathology tools to improve the accuracy of cancer detection and reduce the chances of human error. These technologies can analyze large datasets, identify patterns, and make predictions that can assist clinicians in making more informed decisions. The growing adoption of AI-driven diagnostic platforms is expected to enhance the efficiency of gastric cancer screening programs and reduce the time required for diagnosis.
The market is also influenced by the increasing prevalence of gastric cancer in aging populations, particularly in regions with high incidence rates. This demographic shift is expected to drive the demand for more accessible and cost-effective diagnostic solutions. Governments and healthcare organizations in these regions are investing in public health initiatives aimed at improving cancer screening and early detection rates, which is likely to further boost the market for diagnostic products and services.
However, the market faces challenges, such as high costs associated with advanced diagnostic technologies and the need for specialized expertise to interpret complex diagnostic results. Additionally, disparities in healthcare infrastructure and access to advanced diagnostics between developed and developing regions may limit market growth in certain areas. Despite these challenges, the overall outlook for the gastric cancer diagnostics market remains positive, with continuous innovations and increasing emphasis on early detection poised to significantly impact the landscape in the coming years.
Get a sneak peek at the gastric cancer diagnostics market dynamics @ Gastric Cancer Diagnostics Market Dynamics Analysis
Report Metrics
Details
Coverage
Global
Study Period
2021–2030
Gastric Cancer Diagnostics Market CAGR
~7%
Key Gastric Cancer Diagnostics Companies
Abbott, BD, Bio-Rad Laboratories, Inc., F. Hoffmann-La Roche Ltd, Siemens Healthineers AG, Thermo Fisher Scientific Inc., Pillar Biosciences Inc., Hologic, Inc., CD Genomics, Natera, Inc., Biodesix, Illumina, Inc., Quest Diagnostics, Agilent Technologies, Inc., FUJIFILM Holdings Corporation, NeoGenomics Laboratories, Guardant Health, Myriad Genetics, Inc., Invitae Corporation, Danaher, among others
Gastric Cancer Diagnostics Market Assessment
Gastric Cancer Diagnostics Market Segmentation
Porter's Five Forces Analysis, Product Profiles, Case Studies, KOL's Views, Analyst's View
Which MedTech key players in the gastric cancer diagnostics market are set to emerge as the trendsetter explore @ Gastric Cancer Diagnostics Companies
Table of Contents
1
Gastric Cancer Diagnostics Market Report Introduction
2
Gastric Cancer Diagnostics Market Executive Summary
3
Competitive Landscape
4
Regulatory Analysis
5
Gastric Cancer Diagnostics Market Key Factors Analysis
6
Gastric Cancer Diagnostics Market Porter's Five Forces Analysis
7
Gastric Cancer Diagnostics Market Layout
8
Gastric Cancer Diagnostics Market Company and Product Profiles
9
KOL Views
10
Project Approach
11
About DelveInsight
12
Disclaimer & Contact Us
Interested in knowing the gastric cancer diagnostics market by 2030? Click to get a snapshot of the Gastric Cancer Diagnostics Market Trends
Related Reports
Gastric Cancer Market
Gastric Cancer Market Insight, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key gastric cancer companies, including Hanmi Pharmaceuticals, Merck, Minneamrita Therapeutics, Taiho Pharmaceuticals, Bayer, among others.
Gastric Cancer Pipeline
Gastric Cancer Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key gastric cancer companies, including BeiGene, Linton Pharm Co. Ltd., RAPT Therapeutics, Leap Therapeutics, Idience, Bolt Biotherapeutics, Hubro Therapeutics, Immunocore, Ambrx, Hangzhou DAC Biotech, Beijing Immunoah Pharma Tech, Base Therapeutics, Nanjing KAEDI Biotech, HiberCell, Transcenta Holding, Suzhou Zelgen Biopharmaceuticals, Daiichi Sankyo, Ipsen, Alligator Bioscience, Bristol Myers Squibb, Jiangsu Hengrui Medicine, Shanghai Junshi Biosciences, ImmunoACT, among others.
Gastroesophageal Reflux Disease Market
Gastroesophageal Reflux Disease Market Insight, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key GERD companies, including Phathom Pharmaceuticals, Inc., Microbiome Health Sciences, Takeda, Braintree Laboratories, AstraZeneca, among others.
Gastroesophageal Reflux Disease Pipeline
Gastroesophageal Reflux Disease Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key GERD companies, including Cinclus Pharma, Onconic Therapeutics, Renexxion, Addpharma, Trio Medicines, Chong Kun Dang Pharmaceutical, HK inno.N Corporation, among others.
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Contact UsShruti Thakurinfo@delveinsight.Com+14699457679https://www.Delveinsight.Com/medical-devices
Logo: https://mma.Prnewswire.Com/media/1082265/3528414/DelveInsight_Logo.Jpg
Cision
View original content:https://www.Prnewswire.Com/news-releases/global-gastric-cancer-diagnostics-market-is-expected-to-expand-at-a-cagr-of-7-by-2030--delveinsight-302236389.Html
SOURCE DelveInsight Business Research, LLP
View comments
'Early Detection Is Number 1' — Cheaper, Easier Cancer Screenings Aim To Save Lives Coloradans' Lives
Prev NextThe Colorado Cancer Screening Program says many of the most common and deadly cancers are very treatable when caught early.
DENVER — What you eat, how old you are and even your race or ethnicity could put you at higher risk for cancer. But there's a lot you can do to prevent cancer or at least detect it earlier to improve your treatment options and outcomes.
Denver7 sat down with Andrea Dwyer, who leads the Colorado Cancer Screening Program at the University of Colorado Anschutz, to learn about early screening.
Most Coloradans only go to clinics or hospitals when they feel sick, but Dwyer said we need to change that.
'Early detection is No. 1' — Cheaper, easier cancer screenings aim to save lives
"Early detection is No. 1," Dwyer said. Many of the most common and deadly cancers are "oftentimes very preventable," she said. That includes lung, breast, colorectal and cervical cancers.
Those screenings are covered by most health insurance plans or offered for free to those who are uninsured or underinsured.
"With the Affordable Care Act, and in Colorado, being one of the expansion states, we've seen incredible coverage for preventive services," Dwyer said.
But many Coloradans still aren't getting tested, especially in Latino and Black communities, as well as rural or frontier areas of the state.
Local
Cancer risk is higher for Colorado's Latinos. Here's whyAngelika Albaladejo
Some of the reasons those communities aren't accessing screenings include the potential cost, the challenges of traveling to see a doctor and stigma.
For many, there's discomfort around talking about cancer or symptoms you might be experiencing. Dwyer's heard things like: "That's sort of weird. It's sort of gross. I don't want to talk about those sort of things."
"Screening is sometimes very taboo, especially for colon and rectal cancer," she said.
She's seen the stigma strongest among men in the Latino and Black communities. But for those hesitating to get screened with a more invasive colonoscopy, she said new options are available for simple tests you can do at home. FIT kits, short for Fecal Immunochemical Test, can detect hidden blood in your stool – diagnosing issues early when they're most treatable.
Colorado's Cancer Center is also reaching out to hesitant men with messages about getting screened for the good of your family and community.
"You really need to take care of yourself so you can really be there for others," Dwyer said. "You change the oil in your car. Why shouldn't you really look at checkups for yourself?"
Even if you feel fine, Dwyer said your risk goes up as you get older, and more people are getting diagnosed with cancer at a younger age. Latinos get diagnosed on average at roughly a decade younger than other races and ethnicities.
State News
Colorado ovarian cancer survivor encourages other women to get checked outJaclyn Allen
It's recommended you start getting screenings for breast cancer as early as 40 years old, for colorectal cancer by 45 and for lung cancer around 50, according to guidelines from the Cancer Screening Program.
You may want to get screened earlier than those ages if you have any family members who experienced cancer or you're noticing signs or symptoms. Look out for red flags like blood in your stool, unexplained weight loss of 10 or more pounds and feeling overly tired despite getting rest.
If you're nervous about getting screened, Dwyer said many less invasive types of tests are becoming available as technology grows – so you'll continue having more options to choose from.
To get you started, here are some cancer screening resources currently available in Colorado:
This story is the second in a series. The other parts about why disparities exist and how patient navigators are making it easier to manage care will air on Monday, Sept. 9 and Friday, Sept. 13.
Coloradans making a differenceDenver7 featured videos
Nordstrom teams up with nonprofit to give 350 pairs of shoes to Denver elementary students
Proposition 129 could change delivery of veterinary care in Colorado
Trump promises 'large deportations' in Aurora during Friday press conference
The transition back into society after incarceration is difficult. A Castle Rock woman is trying to ease it
Cherry Creek School District taps college students to address teacher shortage
Denver7 is committed to making a difference in our community by standing up for what's right, listening, lending a helping hand and following through on promises. See that work in action, in the videos above.
Copyright 2024 Scripps Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Space-based Experiments To Advance Early Cancer Detection Through Blood Tests
Feature Story5-Sep-2024
University of Notre Dame researchers are leveraging the International Space Station National Laboratory to enhance biosensing technology for earlier cancer detection
image:
ISS National Lab Commercial Service Provider Space Tango worked with Luo's team to develop specialized CubeLab hardware to automate the study of bubble formation and behavior in microgravity.
view moreCredit: University of Notre Dame
CAPE CANAVERAL (FL), September 3, 2024 – The University of Notre Dame is leading a series of groundbreaking experiments onboard the International Space Station (ISS) to revolutionize early cancer detection. This research, featured in the latest issue of Upward, official magazine of the ISS National Laboratory®, demonstrates how bubbles formed in microgravity can significantly enhance biosensing technology by concentrating microscopic substances more effectively than on Earth.
The just-completed third experiment, which launched to the ISS on Northrop Grumman's 21st Commercial Resupply Services mission to the orbiting laboratory, contracted by NASA, builds on the team's earlier ISS National Lab-sponsored research. This most recent investigation successfully introduced laser heating to refine bubble behavior, increasing the concentration of particles collected—an essential step toward detecting early cancer biomarkers and other trace elements in blood. These advancements could dramatically improve the sensitivity of biosensors, opening the door to earlier and more accurate cancer detection.
"The technology currently available to screen for early, asymptomatic cancer before a tumor is visible during imaging is very limited to just a few cancers," says principal investigator Tengfei Luo, associate chair in the department of aerospace and mechanical engineering at the University of Notre Dame, in the Upward article. "If cancer screening using our bubble technology in space is democratized and made inexpensive, many more cancers can be screened, and everyone can benefit. It's something we may be able to integrate into annual exams. It sounds far-fetched, but it's achievable."
ISS National Lab Commercial Service Provider Space Tango worked with Luo's team to develop specialized CubeLab hardware to automate the study of bubble formation and behavior in microgravity. The hardware includes advanced imaging systems designed to capture high-resolution data on bubble dynamics.
"We're using the unique space environment to push the boundaries of what's possible in biosensing," Luo said. "Our ultimate goal is to make these powerful diagnostic tools widely accessible and affordable on Earth and to accelerate diagnostics that are only possible in space."
For more details about the ongoing research, read the full article in Upward.
Download a high-resolution photo: University of Notre Dame scientists
Disclaimer: AAAS and EurekAlert! Are not responsible for the accuracy of news releases posted to EurekAlert! By contributing institutions or for the use of any information through the EurekAlert system.
Comments
Post a Comment